Mesosil Antibacterial Dental Material Receives FDA Approval, Controlled-Release Technology Expected to Reduce Secondary Caries Risk by 80%

Image Source: Mesosil Official Website

DentalGoodNews | March 29, 2026 - Mesosil, a startup founded by University of Toronto alumnus Cameron Stewart, announced that its antibacterial dental biomaterial has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Utilizing nanotechnology, this material is designed to address the core pain point of restoration failure—secondary caries caused by bacterial infiltration—by enabling the sustained release of antibacterial agents at the interface between the tooth and the filling.

According to the company's disclosure, Mesosil's core technology is based on Porous Silica Particles, which enable the controlled release of antibacterial agents at the restoration interface. Their disclosed laboratory data indicates that this technology can reduce the incidence of secondary caries by approximately 80%, while also effectively enhancing the bonding strength of restorations and slowing material degradation.

Image Source: Responsive antimicrobial dental adhesive based on drug-silica co-assembled particles

Founded in 2018, Mesosil's technological prototype originated from the research conducted by its founder, Cameron Stewart, during his Ph.D. studies at the University of Toronto. According to disclosures from the University of Toronto, the company also secured $2.3 million in funding in 2024 and continues to maintain collaborative research ties with the university.

Regarding its business model, Mesosil states that it does not sell directly to clinicians but instead supplies materials and technology to dental manufacturers. Currently, the company's additive products can be integrated into existing dental composites, cements, and sealants without altering clinicians' current workflows.

Following the FDA clearance, Mesosil will focus on scaling up production and establishing global industry partnerships to promote the commercial application of anti-infective restorative materials. CEO Cameron Stewart stated that the technology also holds potential for expansion into broader medical device fields such as orthopedics and implantable devices in the future.